RYC(SZ:003010) Hua Yuan Zheng Quan·2025-10-30 08:58Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company reported a 73% year-on-year growth in net profit attributable to shareholders for Q3 2025, driven by strong performance in its proprietary brands [5][7] - The company achieved a revenue of 2.14 billion yuan in the first three quarters of 2025, representing an 85% year-on-year increase [7] - The proprietary brand business contributed significantly to revenue, accounting for 55.1% of total revenue in Q3 2025 [7] Financial Performance Summary - Revenue projections for the company are as follows: - 2023: 1,366 million yuan - 2024: 1,766 million yuan (12.25% growth) - 2025E: 3,159 million yuan (78.89% growth) - 2026E: 4,146 million yuan (31.27% growth) - 2027E: 5,005 million yuan (20.71% growth) [6] - Net profit attributable to shareholders is projected to grow from 54 million yuan in 2023 to 350 million yuan in 2027, with growth rates of 60.83%, 94.58%, 70.93%, 42.90%, and 35.61% respectively [6] - The company's gross margin improved by 12.0 percentage points to 58.5% in the first three quarters of 2025 [7] Brand Performance - The proprietary brand "Zhanjia" generated 227 million yuan in revenue in Q3 2025, marking a 118.9% year-on-year increase [7] - The brand "Feicui" achieved revenue of 203 million yuan in Q3 2025, with a sequential growth of over 98.8% [7] - The newly launched brand "Niuyibei" contributed 12.13 million yuan in revenue by September 2025, with significant growth in GMV [7] Brand Management - The brand management business generated 539 million yuan in revenue in the first three quarters of 2025, a 71.1% year-on-year increase [7] - The company focuses on the health and personal care sectors, enhancing its brand management ecosystem and operational capabilities [7]